Clinical evaluation of new biomarkers in diagnosis of valproate-induced renal tubular dysfunction.

Clinical evaluation of new biomarkers in diagnosis of valproate-induced renal tubular dysfunction. - Clinical evaluation of new biomarkers in diagnosis of valproate-induced renal tubular dysfunction.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015787

Enrollment

100

Registered

2014-12-01

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Epilepsy patients treated with valproate and whom treated with anti-epileptic drugs except for valproate.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients treated with valproate for more than 3 months.

Exclusion criteria

Exclusion criteria: The patients with renal diseases.

Design outcomes

Primary

Measure	Time frame
L-FABP(L-type fatty acid binding protein) could be a most sensitive biomarker for diagnosis of valproate-induced renal dysfunction.	—

Countries

Japan

Contacts

Public ContactAtsushi Araki

Kansai medical university Department of Pediatrics

araki@takii.kmu.ac.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026